Maria M. Buryak

Maria M. Buryak

Auto-generated profile, based on publicly available information

Maria M. Buryak

North-Western State Medical University Named After I.I. Mechnikov

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Russian Journal of Human Reproduction
Verified
Journal Article
Closed access
NAN.V. Aganezova
N.V. Aganezova
SAS.S. Aganezov
S.S. Aganezov
MSM.M. Shilo
M.M. Shilo
В статье представлены современные данные о распространенности миомы матки, факторах риска и актуальных теориях патогенеза заболевания. Описаны наиболее распространенные симптомы лейомиомы матки и их значение для соматического и репродуктивного здоровья женщин, а также для качества жизни пациенток. Приведены сведения о влиянии различных терапевтических средств, в том числе эстроген-гестагенных препаратов, на клинические проявления миомы матки. Описаны результаты современных исследований протективных эффектов комбинированных оральных контрацептивов в отношении миомы матки. Представлены данные оценки качества жизни пациенток с лейомиомой матки на фоне использования комбинированных контрацептивов.

22 April 2025 in Journal of obstetrics and women's diseases
Verified
Journal Article
Open access
PDF file
MBMaria M. Buryak
Maria M. Buryak
SASergey S. Aganezov
Sergey S. Aganezov
NANatalia V. Aganezova
Natalia V. Aganezova
БМБуряк Мария Михайловна
Буряк Мария Михайловна
BACKGROUND: In some cases, women with uterine fibroids have heavy menstrual bleeding and dysmenorrhea. Combined hormonal contraceptives are used both for contraception and to alleviate the clinical manifestations of uterine fibroids that do not require surgical treatment. Publications on the effect of combined hormonal contraceptives on the clinical course of uterine fibroids are rare. AIM: The aim of this study was to evaluate the characteristics of menstrual function, as well as clinical and biochemical blood test parameters, blood lipid spectrum and hemostatic screening test parameters in dynamics in women with uterine fibroids using low-dose multiphasic and monophasic combined hormonal contraceptives with ethinyl estradiol. MATERIALS AND METHODS: This study included 148 women, out of whom there were 118 patients with uterine fibroids without indications for surgical treatment [54 patients used multiphasic (ethinyl estradiol ans desogestrel) and monophasic (ethinyl estradiol and various gestagens) combined hormonal contraceptives, 64 patients did not] and 30 healthy participants using combined hormonal contraceptives with ethinyl estradiol. At baseline, after six and 12 months, the study participants were assessed for the duration, volume, and painfulness or painlessness (visual analogue scale, McGill pain questionnaire) of menstrual blood loss, as well as laboratory examination parameters. RESULTS: In women with uterine fibroids using various combined hormonal contraceptives (n = 54), a decrease in the duration (5.6 ± 1.2, 4.1 ± 1.0, and 4.1 ± 1.2 of a day respectively; p 0.05) and volume of menstrual bleeding was noted after 6 and 12 months. 6 of 16 patients with uterine fibroids and heavy menstrual bleeding used combined hormonal contraceptives (2 patients used multiphasic contraceptives, and 4 others monophasic ones). In these 6 women, normal hemoglobin (124–132 g/l) and ferritin (35.4–42.4 μg/l) levels were recorded after 12 months. In patients with uterine fibroids, a reduction in dysmenorrhea or a decrease in its intensity was observed with the use of multiphasic (n = 7; 5.1 ± 1.5, 2.0 ± 0.7, and 1.6 ± 0.5 of a point, respectively) and monophasic (n = 2; 4.6 ± 1.2, 3.7 ± 1.1, and 3.0 ± 0.4 of a point, respectively) combined hormonal contraceptives (p 0.05). No changes were recorded in the initially normal parameters of biochemical blood analysis, lipidogram and coagulogram in the study participants. CONCLUSIONS: The use of multi- and monophasic combined hormonal contraceptives with ethinyl estradiol in patients with uterine fibroids leads to a decrease in the duration and volume of menstrual blood loss. It helps maintain normal levels of hemoglobin and ferritin and reduce the frequency and intensity of dysmenorrhea associated with uterine fibroids. Apart from that, it does not lead to changes in the parameters of biochemical blood analysis, blood lipid spectrum and hemostatic screening in the absence of contraindications to the use these drugs.

27 May 2024 in Journal of obstetrics and women's diseases
Verified
Journal Article
Closed access
PDF file
NANatalia V. Aganezova
Natalia V. Aganezova
SASergey S. Aganezov
Sergey S. Aganezov
MBMaria M. Buriak
Maria M. Buriak
БМБуряк Мария Михайловна
Буряк Мария Михайловна
BACKGROUND: Currently, there is an elevation in the incidence of uterine fibroids in increasingly younger women of reproductive age. Taking into account the current trend of late motherhood, this cohort of patients is interested in using reliable reversible contraception. Combined hormonal contraceptives meet these criteria and are able to neutralize the clinical manifestations of uterine fibroids, thereby improving the quality of life of patients. At the same time, some combined hormonal contraceptives users may experience a decrease in libido and a change in their psycho-emotional state as a manifestation of the side effects of these drugs. AIM: The aim of this study was to assess the effect of combined hormonal contraceptives on the quality of life in patients with uterine fibroids. MATERIALS AND METHODS: This study involved 100 patients with uterine fibroids (F3–F6 according to classification of the International Federation of Gynecology and Obstetrics, without indications for surgical treatment) and 30 healthy women aged 18 to 49 years. For contraceptive purposes, 40 participants with uterine fibroids used combined hormonal contraceptives containing ethinyl estradiol (group I) and 60 patients with uterine fibroids did not use any medications (group II). The following validated questionnaires were used for patients with uterine fibroids — at the beginning and after 6 months, and for healthy women in the control group (group III) — once upon entry into the study: Short Form-36, Female Sexual Function Index, and Beck Depression Inventory. A comparative statistical analysis of the studied parameters over time was carried out. RESULTS: At baseline, a lower quality of life was noted in patients with uterine fibroids compared to the control group (Short Form-36): 94 ± 6 vs 102 ± 11 points, respectively (p 0.05). After 6 months, patients in group I showed positive dynamics with increasing in the total Short Form-36 from 95 ± 4 to 98 ± 5 points (p 0.05) compared to patients in group II: 94 ± 6 and 93 ± 5 points (p 0.05). We revealed no changes in the Female Sexual Function Index in the study groups — at baseline: 24.8 ± 8.9 (group I), 23.9 ± 9.5 (group II), and 27.8 ± 4.7 (group III); and after 6 months: 26.4 ± 9.2 (group I) and 23.9 ± 10.0 (group II) (p 0.05 for all comparisons). When comparing the results of a questionnaire on the Beck scale, no dynamics were determined in patients with uterine fibroids, including those who used combined hormonal contraceptives. CONCLUSIONS: The study demonstrated a lower quality of life in patients with uterine fibroids compared to healthy women and an improved quality of life in patients with uterine fibroids using combined hormonal contraceptives. We showed no negative effects of contraceptive drugs on libido and emotional state in women with uterine fibroids who used combined hormonal contraceptives for 6 months.

22 April 2025 in Journal of obstetrics and women's diseases
Verified
Journal Article
Closed access
PDF file
NANatalia V. Aganezova
Natalia V. Aganezova
SASergey S. Aganezov
Sergey S. Aganezov
MBMaria M. Buryak
Maria M. Buryak
БМБуряк Мария Михайловна
Буряк Мария Михайловна
BACKGROUND: The increasing prevalence of uterine fibroids at the age of 20–35 years and late fertility intentions are modern trends in women’s lives. Combined hormonal contraceptives level out cyclic fluctuations of sex steroids in the natural menstrual cycle; can be used by patients with fibroid nodes for contraception; and have a protective effect on uterine fibroids. The literature does not provide comparative data on the use of multi- and monophasic combined hormonal contraceptives with ethinyl estradiol by patients with uterine fibroids. AIM: The aim of this study was to assess the characteristics of fibroid nodes in dynamics in women using multiphasic and monophasic combined hormonal contraceptives. MATERIALS AND METHODS: This study included 554 women. Prospective part of the research involved 118 patients with uterine fibroids without indications for surgical treatment: 54 patients used multiphasic (ethinyl estradiol and desogestrel) and monophasic (ethinyl estradiol and various gestagens) combined hormonal contraceptives, and 64 patients did not. Who underwent pelvic ultrasound examination three times over 12 months. Retrospective part of the research included analysis of in-person instrumental-clinical-anamnestic data obtained from 436 women (45 patients with fibroid nodes and 391 healthy individuals). Out of the 391 healthy participants, 297 ones used various combined hormonal contraceptives with ethinyl estradiol for 1–30 years, while the other 94 did not. RESULTS: In women with uterine fibroids using various combined hormonal contraceptives with ethinyl estradiol (n = 94), no changes in the sizes of classification of International Federation of Gynaecology and Obstetrics (FIGO) types 3 to 6 fibroid nodes were observed (n = 124; 21.7 ± 2.8 vs. 21.5 ± 3.2 mm; p 0.05). In patients with FIGO type 4 fibroid nodes using multiphasic combined hormonal contraceptives (n = 20), a decrease in the size of the nodes was registered after 12 months (n = 14; 15.7 ± 3.4 vs. 14.1 ± 2.7 mm; p 0.05). In 17 (5.7%) healthy participants using combined hormonal contraceptives and in 15 (16.0%) patients without fibroid nodes who did not use these drugs, uterine fibroids were first diagnosed in the reproductive period. CONCLUSIONS: The use of various combined hormonal contraceptives by patients with uterine fibroids did not lead to an increase in the size of FIGO types 3 to 6 fibroid nodes with an initial diameter of up to 22 mm. After 12 months, we noted a decrease in the size of F4 type fibroid nodes with an initial diameter of up to 16 mm for the women with uterine fibroids, who took multiphasic combined hormonal contraceptives. In women of reproductive age who used combined hormonal contraceptives for 1–30 years, uterine fibroids were first diagnosed 2.8 times less often than in patients who did not use these drugs.

18 May 2023 in Journal of obstetrics and women's diseases
Verified
Journal Article
Closed access
PDF file
NANatalia V. Aganezova
Natalia V. Aganezova
SASergey S. Aganezov
Sergey S. Aganezov
MSMaria M. Shilo
Maria M. Shilo
BACKGROUND:Uterine fibroids are increasingly diagnosed in patients of reproductive age. Combined hormonal contraceptives provide reliable protection against unwanted pregnancy and help to reduce or eliminate various clinical manifestations of uterine fibroids. In practice, obstetrician-gynecologists have barriers to prescribing combined hormonal contraceptives to patients with uterine fibroids. AIM:The aim of this work was to study the features of the clinical approach of obstetrician-gynecologists to the management of patients with uterine fibroids interested in combined hormonal contraception. MATERIALS AND METHODS:The method of voluntary anonymous questioning was applied to 366 obstetrician-gynecologists. The work experience of 62.1% (n= 227) of doctors was 10 years or more. The questionnaire included questions about various aspects of the use of combined hormonal contraceptives for contraception in women with uterine fibroids. RESULTS:Only every second (47.5%;n= 174) obstetrician-gynecologist correctly assigns uterine fibroids to the first category of acceptability for combined hormonal contraceptives. The presence of an asymptomatic submucous myomatous node (FIGO 12) or dysmenorrhea in women with uterine fibroids is considered by 29.0% (n= 106) and 5.7% (n= 21) of obstetrician-gynecologists, respectively, as a contraindication to the use of combined hormonal contraceptives. Every ninth participant (11.4%;n= 42) believes that the presence of uterine fibroids limits the duration of use of combined hormonal contraceptives for contraception to 15 years. Almost half (45.6%;n= 167) of the respondents believe that combined hormonal contraceptives have various effects on uterine fibroids (cause regression or growth of fibroids, increase the risk of new fibroids). More than half (53.3%;n= 195) of the respondents are not informed about the reduction in the risk of developing uterine fibroids when using combined hormonal contraceptives for five years or more. CONCLUSIONS:In the analyzed cohort of experienced obstetrician-gynecologists, we identified their barriers to prescribing combined hormonal contraceptives for contraception for women with uterine fibroids. Those are incomplete awareness of the acceptance criteria for combined hormonal contraceptives and insufficient awareness of the lack of effect of combined hormonal contraceptives on the size of existing myomatous nodes and a decrease in the risk of developing uterine fibroids when using combined hormonal contraceptives for five or more years.

23 April 2024 in Russian Journal of Human Reproduction
Verified
Journal Article
Closed access
NAN.V. Aganezova
N.V. Aganezova
SAS.S. Aganezov
S.S. Aganezov
MBM.M. Buryak
M.M. Buryak
Background. An increasing number of young women with uterine fibroids are postponing childbearing and using combined hormonal contraceptives (CHCs). 20-30% of users report side effects of CHCs, including changes in libido and mood. Objective. To study in a comparative aspect the tolerability of multiphasic and monophasic CHCs with ethinyl estradiol (EE) in patients with uterine fibroids. Materials and methods. 113 women (18—45 years old) were included. Group I (n=26): patients with uterine fibroids who used multiphasic CHCs, II (n=57) — monophasic CHCs; III (n=30) — healthy women who used monophasic CHCs. Side effects of CHCs, sexual function (Female Sexuality Index, FSFI), psychoemotional state (Beck Depression Inventory), quality of life (SF-36) and satisfaction with the use of drugs were assessed. Results. A more frequent occurrence of intermenstrual bleeding from the vagina was recorded in the first 3 months of using microdose monophasic (30%) compared to multiphasic (8%) CHCs in patients with uterine fibroids (p0.05). The psycho-emotional state of the participants did not change over 6 months of observation (7.5±3.1; 7.4±3.2; 7.2±3.9; p>0.05). Initially, a lower quality of life was noted in patients with uterine fibroids than in healthy women (SF-36 points): 95±5 (I—II); 103±11 (III) (p<0.05). After 6 months, patients with uterine fibroids using CHCs showed an increase in the overall SF-36 score from 94±4 to 101±10 (I) and from 95±6 to 101±9 (II) points, respectively (p<0.05). Satisfaction with the use of CHC was 98% and did not differ between study groups. Conclusions. In the first 3 months of using multiphasic CHCs, less frequent episodes of irregular intermenstrual bleeding from the vagina were noted. The incidence of other side effects of CHCs did not differ between study groups and was not dependent on the daily dose of EE in the CHC. The use of multiphasic and monophasic CHCs with EE by study participants did not have a negative effect on their libido and mood. In patients with uterine fibroids, the use of both multiphasic and monophasic CHCs with EE leads to a significant improvement in the quality of life. 98% of study participants were satisfied with the use of CHCs of various phases.